“Quinnova Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercial sale of prescription drug products based on innovative dermal drug delivery platforms. Quinnova employs a “reformulation strategy” whereby already-proven safe and effective pharmaceutical ingredients are delivered in unique, effective, convenient, cosmetically elegant and patent protected delivery systems. By employing this “reformulation strategy,” Quinnova is able to bring revenue-generating prescription products to the commercial market on a relatively short development timeline. Quinnova’s portfolio of versatile drug delivery systems lends itself to corporate partnering opportunities beyond the prescription products Quinnova develops in-house. ”
(Source Quinnova)
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 11/01/06 | Series A | 13.6M | H.I.G. Capital, Thomas, McNerney & Partners | Unknown |
People
Lincoln Krochmal (Board Member)
Alex Zisson (Board Member)
Jeffrey S. Day (President)
Christopher S. Brennan (EVP Operations & General Counsel)
G. Frits Besselaar (Board Member)
View more details about all 8 people at Quinnova Pharmaceuticals
